Engineered immune cells take aim at advanced prostate cancer
NCT ID NCT01140373
First seen Dec 09, 2025 · Last updated May 25, 2026 · Updated 29 times
Summary
This early-phase study tests a new approach for men with advanced prostate cancer that no longer responds to hormone therapy. The patient's own immune cells (T cells) are collected, genetically modified in a lab to better recognize and attack prostate cancer cells, and then infused back. The main goal is to check safety and find the right dose, with 13 participants enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.